AIP Conference Proceedings
Analysis of the relationship between fetal health prediction features with machine learning Feyn QLattice regression model.
Abzu® and Contera Pharma expand strategic partnership to add target identification to RNA therapeutic design platform.
The application designs RNA therapeutics through parallel hypotheses testing of drug targets and individual antisense oligonucleotide (ASO) drug properties.
Senior Pharma Business Developer
We are looking for an experienced business developer who wants to build commercial partnerships within the pharmaceutical and life science industries.
NASA GeneLab 2023 AWG Symposium: The year of open science.
Abzu’s Jonas Elsborg presents his research with NASA GeneLab: “Elucidating dermatological changes in spaceflight with explainable AI.”
Information fusion via symbolic regression: A tutorial in the context of human health.
The TOLAC project.
The TOLAC project brings data-driven insights to expectant parents at important stages of pregnancy to reduce the risk inherent in vaginal or caesarian delivery.
SAE Media Group’s 14th Annual Conference – RNA Therapeutics.
Investigating the next generation of genetic medicine through RNA-based therapies.
Deep Tech Stories: Part 2
Part 2 with Casper Wilstrup: Self-management, transparency, and a new kind of AI to revolutionize science.
The U.S. Patent and Trademark Office issues patent for the technology behind the pioneering QLattice® algorithm.
Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice algorithm.
Abzu® becomes a vetted member of the Nordic Ethical AI Landscape.
Launched in collaboration with the Ethical AI Governance Group (EAIGG) and the Ethical AI Database (EAIDB), the Nordic Ethical AI Landscape is the only publicly available, vetted database of AI companies in the Nordics that provide ethical services.